Abstract
Objective: This study aimed to compare the effects of N-acetyl cysteine on renal function after coronary artery bypass graft surgery.Method: In this randomized clinical trial conducted in Golestan Hospital, Ahvaz, Iran, 60 candidates for coronary artery bypass graft surgery were selected and divided into two N-acetyl cysteine and control groups (30 people each).Intervention: Patients received 3 (2 intraoperative and 1 postoperative) doses of IV N-acetyl cysteine (100 mg/kg) (n=30) or placebo (n=30) over 24 hour. Prescription times were as follows: after induction of anesthesia, in the Next 4 hours, and in the 16 hours after on. Primary outcomes were serum levels of BUN and Cr, at baseline,4 and 48 hours after surgery. And also need renal replacement therapy (RRT). Secondary outcomes included the hemodynamic variables, Blood products transfusionResults: There were significant differences in BUN between groups at 4 h (P= 0.02) and 48h after surgery (P=0.001) There were significant differences in Cr level between groups at 4 h (P <0.001) and 48h after surgery (P=0.001). MAP at different times (at 4h p=0.002 and 48h after surgery P<0.001) were significantly different between the two groups. There was a significant difference between the two groups in terms of the unit of Packed cell transfusion (P=0.002) and FFP transfusion (P<0.001).Conclusion: In the present study, we found that administration of N-acetyl cysteine can reduce the incidence of acute kidney injury in patients undergoing coronary artery bypass graft surgery and improved kidney functions.Trial registry: IRCT20190506043492N3 Registered at 2020.06.07